M&As this week: Northern Biologics, Sumitomo Dainippon Pharma, Premaitha Health

Canadian-based biotechnology company Northern Biologics has merged with Mosaic Biomedicals, a biotechnology company located in Spain.

Northern Biologics will provide financial resources for the development of MSC-1 under the merger.

Sumitomo Dainippon Pharma has announced its decision to acquire Tolero Pharmaceuticals for an upfront payment of $430m.

Sumitomo Dainippon Pharma will be responsible for paying an additional $150m to Tolero Pharma for commercial milestone payments.

The acquisition will enable the acquirer company to expand its presence in the oncology market.

Premaitha Health has announced it will acquire Yourgene Biosciences for a purchase consideration of $8.97m.

Cairn Financial Advisers is the acting advisor for the acquisition.

The acquisition enables Premaitha Health to expand its market access in Asia and benefit from cross selling opportunities.

Dipexium Pharmaceuticals has entered an agreement to merge with PLx Pharma.

Upon completion of the merger in the second quarter of the year, Dipexium Pharma will be renamed PLx Pharma and operate under the leadership of the PLx Pharma management team.

The combined company will focus on manufacturing scale-up and label finalisation for the previously conditionally approved Aspertec 325mg aspirin dosage form.

Dipexium Pharma is assisted by Raymond James & Associates as financial advisor, along with Mintz, Levin, Cohn, Ferris, Glovsky and Popeo as legal advisor.

PLx Pharma is receiving assistance from Janney Montgomery Scott as financial advisor and Jackson Walker as legal advisor.

Chengdu Tianxing Instrument & Meter has agreed to acquire Berry Genomics in a reverse takeover transaction for $619m.

As per the agreement, Chengdu Tianxing Instrument & Meter will carry out the acquisition through an asset exchange via issuing new shares to Berry Genomics.

Da An Gene of Sun Yat-sen University has decided to sell a 4.98% stake in a Guangzhou-based pharmaceutical technology company for a purchase consideration of ¥59.8m ($8.6m).

Taisho Pharmaceutical, a subsidiary of Taisho Pharmaceutical Holdings, has agreed to acquire skin care products provider Dr Program.

A 19.99% stake in BiondVax Pharmaceuticals, a biopharmaceutical company based in Israel, has been acquired by investment company Angels High Tech Investments.

The purchase consideration for the minority acquisition involving 33.8 million ordinary shares is $2.83m.

BiondVax plans to use the investment to complete the development and commercialisation of its universal influenza vaccine candidate worldwide.

Acura Pharmaceuticals is looking for potential acquirers to sell itself.

The company simultaneously is looking for alternative transactions such as capital raising, licensing and a sale of certain assets.